GPX4-IN-19
Based on 1 Customer Validation
GPX4-IN-19 is an effective GPX4 inhibitor (IC50 = 0.311 μM), covalently binds to the Sec 46 site of GPX4. GPX4-IN-19 shows strong anti-proliferative activity with high ferroptosis selectivity. GPX4-IN-19 causes intracellular Fe2+ accumulation, leading to increased levels of lipid peroxides (LPOs) and reactive oxygen species (ROS), which induces ferroptosis and subsequently results in DNA damage. GPX4-IN-19 can be used for the study of Triple-Negative Breast Cancer (TNBC).
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 99.45%
- CAS 番号: 3102894-57-2
- 分子式: C19H19ClFNO5
- 分子量:395.81
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
DNA/RNA Synthesis アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
体外実験
GPX4-IN-19 (Compound Y19) (72 h) exhibits effective anti-proliferative activity to six cancer cell lines (MCF-7, MDA-MB-231, PC-3, MDA-MB-468, PANC-1, and ASPC-1) (IC50: 0.021-0.094 μM)[1].
GPX4-IN-19 (12.5-50 nM, 2 weeks) can effectively inhibit cell proliferation, and the addition of the inhibitor Ferrostatin-1 (HY-100579) (Fer-1) reversed the inhibition of cell proliferation in MDA-MB-231 cells[1].
GPX4-IN-19 (50 nM, 8 h) can cause mitochondria in the cells to show typical morphological changes, such as rupture of the outer mitochondrial membrane, smaller mitochondrial volume, and reduction or absence of inner mitochondrial crista in MDA-MB-231 cells[1].
GPX4-IN-19 (12.5-50 nM, 8 h) induces dose-dependent increases in intracellular Fe2+ concentration, LPOs accumulation, MDA content, and ROS level in MDA-MB-231 cells[1].
GPX4-IN-19 (12.5-50 nM, 8 h) causes DNA damage in MDA-MB-231 cells by increasing the expression of γH2AX, and this DNA damage is significantly attenuated by the addition of inhibitors such as Fer-1[1].
GPX4-IN-19 (1 μM, 2 h) reduces the degradation temperature of GPX4 protein at the same temperature in MDA-MB-231 cells, indicating that GPX4-IN-19 reduced the thermal stability of GPX4 protein[1].
GPX4-IN-19 (12.5 nM, 25 nM, 50 nM, 8 h) exhibits significant resistance in the MDA-MB-231 cell lines that are resistant to GPX4 inhibitors RSL3 or ML162 (MDA-MB-231-RSL3 and MDA-MB-231-ML162)[1].
GPX4-IN-19 (12.5-50 nM, 4-12 h) reduces GPX4 levels in a concentration-dependent manner in MDA-MB-231 cells. However, time-course analysis reveals that GPX4 expression initially increases at 4 hours, with minimal change in xCT levels at this early time point, but subsequently decreases at 8 hours accompanied by a significant increase in xCT expression[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MDA-MB-231 cells
-
Concentration:12.5 nM, 25 nM, 50 nM
-
Incubation Time:2 weeks
-
Result:Effectively inhibited cell proliferation, and the addition of the inhibitor Fer-1 reversed the inhibition of cell proliferation in MDA-MB-231 cells.
-
Cell Line:MDA-MB-231 cells
-
Concentration:12.5 nM, 25 nM, 50 nM
-
Incubation Time:8 h
-
Result:Increased expression of DNA damage marker γH2AX.
Decreased the level of GPX4 in a concentration-dependent manner.
Didn't inhibit other proteins contained selenium, including Glutathione peroxidase 1 (GPX1) and Thioredoxin reductase 1 (TXNRD1).
FTH1 was significantly decreased with the concentration change.
Increased ACSL4 expression levels.
-
Cell Line:MDA-MB-231 cells
-
Concentration:12.5 nM, 25 nM, 50 nM
-
Incubation Time:8 h
-
Result:Reduced GPX4 level in a concentration-dependent manner in MDA-MB-231 cells.
-
Cell Line:MDA-MB-231 cells
-
Concentration:12.5 nM, 25 nM, 50 nM
-
Incubation Time:4 h, 8 h, 12 h
-
Result:The expression of GPX4 increased at 4 h, and the xCT level of the upstream signaling pathway hardly changed at this time, but the expression level of GPX4 decreased and the expression level of xCT increased at 8h.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:MDA-MB-231 cells (1 × 107 cells in 200 μL suspension, mixed 1:1 with Matrigel and PBS) are subcutaneously injected into the left flank of female BALB/c nude mice (4 to 5weeks old)[1].
-
Dosage:5 mg/kg, 10 mg/kg
-
Administration:I.p., every two days for 24 days
-
Result:Tumor growth was inhibited in a dose-dependent manner, tumor growth inhibition (TGI) of 72.53 % at 10 mg/kg.
Ki67-positive tumor cells were decreased.
GPX4 was significantly decreased compared with the control group.
Revealed no apparent morphological abnormalities in major organs, including the heart, liver, spleen, lungs, and kidneys.
Could not destroy the function of the liver, the kidneys, and the heart.
化学情報
-
CAS 番号 3102894-57-2
-
性状 Solid
-
分子量 395.81
-
分子式 C19H19ClFNO5
-
Color Off-white to light yellow
-
SMILES
COC1=CC(N(C(CCl)=O)CC2=CC3=C(OCCO3)C=C2)=CC(OC)=C1F
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
溶剤 & 溶解度
体外:
DMSO : 50 mg/mL (126.32 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
プロトコル
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
純度とドキュメンテーション
-
データシート (281 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5265 mL | 12.6323 mL | 25.2646 mL | 63.1616 mL |
| 5 mM | 0.5053 mL | 2.5265 mL | 5.0529 mL | 12.6323 mL | |
| 10 mM | 0.2526 mL | 1.2632 mL | 2.5265 mL | 6.3162 mL | |
| 15 mM | 0.1684 mL | 0.8422 mL | 1.6843 mL | 4.2108 mL | |
| 20 mM | 0.1263 mL | 0.6316 mL | 1.2632 mL | 3.1581 mL | |
| 25 mM | 0.1011 mL | 0.5053 mL | 1.0106 mL | 2.5265 mL | |
| 30 mM | 0.0842 mL | 0.4211 mL | 0.8422 mL | 2.1054 mL | |
| 40 mM | 0.0632 mL | 0.3158 mL | 0.6316 mL | 1.5790 mL | |
| 50 mM | 0.0505 mL | 0.2526 mL | 0.5053 mL | 1.2632 mL | |
| 60 mM | 0.0421 mL | 0.2105 mL | 0.4211 mL | 1.0527 mL | |
| 80 mM | 0.0316 mL | 0.1579 mL | 0.3158 mL | 0.7895 mL | |
| 100 mM | 0.0253 mL | 0.1263 mL | 0.2526 mL | 0.6316 mL |